Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Adlai Nortye

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Sep 28, 2022 3:48pm

163 Views

Post# 34993154

RE:RE:RE:Adlai Nortye

Yes it makes sense as the bridging trial was already in progress and some patients had been treated with pela but now no mention of the bridging trial results which should have been done a long time ago and onc is no longer listed in their pipeline of drugs going forward as this is how it used to be mentioned so am still thinking that something has changed. I now no longer see them going forward with the phase 3 for mbc but hope I am wrong as that would also mean no royalites or milestones from this partnership.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec